Indication
Estrogen Receptor Gene Mutation
2 clinical trials
4 products
2 drugs
Clinical trial
A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 InhibitorsStatus: Not yet recruiting, Estimated PCD: 2027-09-01
Product
EverolimusDrug
ElacestrantProduct
PlaceboProduct
DexamethasoneClinical trial
A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients With ESR1 MutationsStatus: Recruiting, Estimated PCD: 2024-12-01
Drug
Tamoxifen